Cargando…
Dermatology patients on biologics and certain other systemic therapies should receive a “booster” messenger RNA COVID-19 vaccine dose: A critical appraisal of recent Food and Drug Administration and Advisory Committee on Immunization Practices recommendations
Autores principales: | Waldman, Reid Alexander, Grant-Kels, Jane M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier on behalf of the American Academy of Dermatology, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381623/ https://www.ncbi.nlm.nih.gov/pubmed/34437985 http://dx.doi.org/10.1016/j.jaad.2021.08.031 |
Ejemplares similares
-
Yellow Fever Vaccine Booster Doses: Recommendations of the Advisory Committee on Immunization Practices, 2015
por: Staples, J. Erin, et al.
Publicado: (2015) -
Tele-2020
por: Heymann, Warren R.
Publicado: (2020) -
Evidence following guidelines: Another COVID-19 paradox
por: Heymann, Warren R.
Publicado: (2021) -
First, and foremost, a physician
por: Schwarzenberger, Kathryn
Publicado: (2021) -
The Advisory Committee on Immunization Practices’ Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021
por: Mbaeyi, Sarah, et al.
Publicado: (2021)